MedTrace Logo

Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

NCT02749292 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2023-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the best management strategy to maintain remission in patients with ANCA vasculitis who have been treated with rituximab induced B cell depletion for at least two years. This study will compare intermittent B Cell depletion upon B cell return or intermittent B cell depletion upon serologic relapse.

Conditions

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

DRUG

Rituximab

re-dosing dependent on interventional arm parameter.

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • John L Niles, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749292 on ClinicalTrials.gov